Arrowhead Pharmaceuticals Inc. Watch

from 10-K 151 pages Execution Version Certain Information in This Document, Marked by [**], Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10)(iv). Such Excluded Information Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. the Following Information Is Supplied Solely for U.S. Federal Income Tax Purposes. the Loans Under This Agreement Are Treated as Having Been Issued With Original Issue Discount (“Oid”) Within the Meaning of Section 1273 of the Internal Revenue Code of 1986, as Amended (The “Code”), and This Legend Is Required by Section 1275(c) of the Code. Information Including the Issue Price, the Amount of Original Issue Discount, the Issue Date and the Yield to Maturity Will Be Provided in Writing to a Lender Promptly Upon Request to the Borrower at 177 E. Colorado Blvd, Suite 700, Pasadena, California 91105, Attn: Chief Financial Officer, Email: Cfo@arrowheadpharma.com. Financing Agreement Dated as of August 7, 2024 Among Arrowhead Pharmaceuticals, Inc., as Borrower, Certain Subsidiaries of Borrower, as Guarantors, Various Lenders From Time to Time Party Hereto, and Sixth Street Lending Partners, as Administrative Agent